Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RUTI vaccine
- Development stage
- Phase 3
- Lead developer
- Archivel Farma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
RUTI is a therapeutic vaccine developed by Archivel Farma, composed of detoxified fragments of *Mycobacterium tuberculosis* (MTB) bacilli cultured under stress conditions to express antigens associated with latency, and encapsulated in liposomes. It is designed to stimulate a broad Th1/Th17 polyantigenic immune response against both active and dormant bacilli, serving as an adjunct to standard antibiotic therapy for tuberculosis (TB), including drug-sensitive, multidrug-resistant (MDR-TB), and latent TB infections. Beyond its primary indication in TB, RUTI is being investigated for its ability to induce "trained immunity"—an epigenetic reprogramming of innate immune cells—to provide non-specific protection against viral infections like SARS-CoV-2 and to enhance the systemic and mucosal immunological response in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) treated with intravesical BCG.
- Brand names
- RUTI
- Other names
- RUTIVAC
Beyond the preview
Go deeper on RUTI vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RUTI vaccine.